2023.09
Congratulations! Pantrone has successfully assisted our client in obtaining FDA IND approval for their Car-T cell product in the U.S.
Pantrone recently collaborated with a leading cell therapy company in Taiwan to secure the first Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for allogeneic Chimeric Antigen Receptor T-cell (Car-T) therapy targeting solid tumors. Remarkably, this approval was granted within just one month after submission. This case stands among the very few globally that have attained IND approval for allogeneic Car-T therapy for cancer.
Pantrone is proud to have played a crucial role in reaching this milestone, demonstrating our commitment to facilitating groundbreaking advancements in the biotechnology field.
2022.07
Congratulations! Pantrone is thrilled to announce the successful assistance provided to our client in obtaining FDA IND approval for their stem cell product in the U.S.
Pantrone has collaborated with a leading cell therapy company in Taiwan to facilitate the first-ever Investigational New Drug (IND) application for Umbilical Cord Mesenchymal Stem Cell (UCMSC) therapy for Multiple Sclerosis (MS) in the United States. The approval was secured within a mere month after submission to the U.S. Food and Drug Administration (FDA).
Pantrone is grateful for the opportunity to contribute to this achievement, reflecting our commitment to assisting our clients in reaching important milestones in biomedical innovation.